慢性丙型肝炎患者治疗率的区域差异：系统综述与荟萃分析

数据集获取（Figshare）

• 源站标题：Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis
• DOI：10.1371/journal.pone.0183851
• 发布日期：2017-09-06
• 文件数：5 个
• 文件总体积：640.33 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Regional_differences_in_treatment_rates_for_patients_with_chronic_hepatitis_C_infection_Systematic_review_and_meta-analysis/5380519

命令行下载

curl -L -o "S1 Table.docx" "https://ndownloader.figshare.com/files/9267865"
curl -L -o "S2 Table.docx" "https://ndownloader.figshare.com/files/9267892"
curl -L -o "S1 Fig.pdf" "https://ndownloader.figshare.com/files/9267925"
curl -L -o "S1 Checklist.docx" "https://ndownloader.figshare.com/files/9267937"
curl -L -o "S1 Database.xlsx" "https://ndownloader.figshare.com/files/9267964"

文件清单

• S1 Table.docx（15.49 KB）
• S2 Table.docx（12.44 KB）
• S1 Fig.pdf（543.23 KB）
• S1 Checklist.docx（17.74 KB）
• S1 Database.xlsx（51.42 KB）

文件总体积 640.33 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background & aims
Treatment rates with interferon-based therapies for chronic hepatitis C have been low. Our aim was to perform a systematic review of available data to estimate the rates and barriers for antiviral therapy for chronic hepatitis C.
Methods
We conducted a systematic review and meta-analysis searching MEDLINE, SCOPUS through March 2016 and abstracts from recent major liver meetings for primary literature with available hepatitis C treatment rates. Random-effects models were used to estimate effect sizes and meta-regression to test for potential sources of heterogeneity.
Results
We included 39 studies with 476,443 chronic hepatitis C patients. The overall treatment rate was 25.5% (CI: 21.1–30.5%) and by region 34% for Europe, 28.3% for Asia/Pacific, and 18.7% for North America (p = 0.008). On multivariable meta-regression, practice setting (tertiary vs. population-based, p = 0.04), region (Europe vs. North America p = 0.004), and data source (clinical chart review vs. administrative database, p = 0.025) remained significant predictors of heterogeneity. The overall treatment eligibility rate was 52.5%, and 60% of these received therapy. Of the patients who refused treatment, 16.2% cited side effects, 13.8% cited cost as reasons for treatment refusal, and 30% lacked access to specialist care.
Conclusions
Only one-quarter of chronic hepatitis C patients received antiviral therapy in the pre-direct acting antiviral era. Treatment rates should improve in the new interferon-free era but, cost, co-morbidities, and lack of specialist care will likely remain and need to be addressed. Linkage to care should even be of higher priority now that well-tolerated cure is available.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0183851（source: https://plos.figshare.com/articles/dataset/Regional_differences_in_treatment_rates_for_patients_with_chronic_hepatitis_C_infection_Systematic_review_and_meta-analysis/5380519）。